Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from LBT Innovations Limited ( (AU:CC5) ).
Clever Culture Systems Ltd achieved a cashflow break-even milestone for operating activities in the December 2024 quarter, driven by increased sales and the expansion of its APAS® Independence instrument within the pharmaceutical industry. Significant orders from pharmaceutical giants like AstraZeneca and Bristol Myers Squibb, coupled with the anticipated launch of the APAS® Contact Plate capability, are expected to enhance the company’s market position and financial outlook. The company is strengthening its sales and marketing efforts, expecting to maintain positive cashflow for the remainder of the financial year 2025, while also adding approximately $400k in annual recurring revenues through service and maintenance transfers.
More about LBT Innovations Limited
Clever Culture Systems Ltd is an Australian medical technology company specializing in microbiology automation through artificial intelligence. It focuses on the pharmaceutical market, offering products like the APAS® Independence instrument for environmental monitoring in pharmaceutical manufacturing.
YTD Price Performance: -15.00%
Average Trading Volume: 1,172,625
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$29.92M
See more insights into CC5 stock on TipRanks’ Stock Analysis page.
